These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 18930377)

  • 41. Prevalence of metabolic syndrome in HIV-infected patients receiving highly active antiretroviral therapy using International Diabetes Foundation and Adult Treatment Panel III criteria: associations with insulin resistance, disturbed body fat compartmentalization, elevated C-reactive protein, and [corrected] hypoadiponectinemia.
    Samaras K; Wand H; Law M; Emery S; Cooper D; Carr A
    Diabetes Care; 2007 Jan; 30(1):113-9. PubMed ID: 17192343
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Waist circumference is the best anthropometric predictor for insulin resistance in nondiabetic patients with schizophrenia treated with clozapine but not olanzapine.
    Henderson DC; Fan X; Sharma B; Copeland PM; Borba CP; Freudenreich O; Cather C; Evins AE; Goff DC
    J Psychiatr Pract; 2009 Jul; 15(4):251-61. PubMed ID: 19625881
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Randomized, controlled, double-blind multicenter comparison of the efficacy and tolerability of ziprasidone and olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder.
    Simpson GM; Glick ID; Weiden PJ; Romano SJ; Siu CO
    Am J Psychiatry; 2004 Oct; 161(10):1837-47. PubMed ID: 15465981
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Fasting hyperinsulinemia associates with increased sub-clinical inflammation in first-degree relatives normal glucose tolerant women independently of the metabolic syndrome.
    Setola E; Monti LD; Lucotti P; Galluccio E; Oldani M; Bosi E; Piatti P
    Diabetes Metab Res Rev; 2009 Oct; 25(7):639-46. PubMed ID: 19685554
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Lifestyle and mood correlates of cardiometabolic risk in people with serious mental illness on second-generation antipsychotic medications.
    Miedlich SU; Sahay P; Olivares TE; Lamberti JS; Morse DS; Brazill KP; Chhabra KH; Bainbridge L
    PLoS One; 2024; 19(8):e0306798. PubMed ID: 39121088
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Ziprasidone's effect on metabolic markers in patients with diabetes and chronic schizophrenia.
    Lindenmayer JP; Tedeschi F; Yusim A; Khan A; Kaushik S; Smith RC; Parakadavil M
    Clin Schizophr Relat Psychoses; 2012 Jan; 5(4):185-92. PubMed ID: 22182455
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Drawing up guidelines for the attendance of physical health of patients with severe mental illness].
    Saravane D; Feve B; Frances Y; Corruble E; Lancon C; Chanson P; Maison P; Terra JL; Azorin JM;
    Encephale; 2009 Sep; 35(4):330-9. PubMed ID: 19748369
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Serum adiponectin concentrations predict the developments of type 2 diabetes and the metabolic syndrome in elderly Koreans.
    Choi KM; Lee J; Lee KW; Seo JA; Oh JH; Kim SG; Kim NH; Choi DS; Baik SH
    Clin Endocrinol (Oxf); 2004 Jul; 61(1):75-80. PubMed ID: 15212647
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Effect of antipsychotics on peptides involved in energy balance in drug-naive psychotic patients after 1 year of treatment.
    Perez-Iglesias R; Vazquez-Barquero JL; Amado JA; Berja A; Garcia-Unzueta MT; Pelayo-Terán JM; Carrasco-Marín E; Mata I; Crespo-Facorro B
    J Clin Psychopharmacol; 2008 Jun; 28(3):289-95. PubMed ID: 18480685
    [TBL] [Abstract][Full Text] [Related]  

  • 50. High-dose olanzapine-induced improvement of preexisting type 2 diabetes mellitus in schizophrenic patients.
    Lerner V; Libov I; Kanevsky M
    Int J Psychiatry Med; 2003; 33(4):403-10. PubMed ID: 15152791
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Plasma adiponectin levels in schizophrenia and role of second-generation antipsychotics: a meta-analysis.
    Bartoli F; Lax A; Crocamo C; Clerici M; Carrà G
    Psychoneuroendocrinology; 2015 Jun; 56():179-89. PubMed ID: 25827962
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Hyperglycemia and antipsychotic medications.
    Haupt DW; Newcomer JW
    J Clin Psychiatry; 2001; 62 Suppl 27():15-26; discussion 40-1. PubMed ID: 11806485
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Insulin resistance and adiponectin levels in drug-free patients with schizophrenia: A preliminary report.
    Cohn TA; Remington G; Zipursky RB; Azad A; Connolly P; Wolever TM
    Can J Psychiatry; 2006 May; 51(6):382-6. PubMed ID: 16786820
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A novel biomarker of cardiometabolic pathology in schizophrenia?
    Lee EE; Sears DD; Liu J; Jin H; Tu XM; Eyler LT; Jeste DV
    J Psychiatr Res; 2019 Oct; 117():31-37. PubMed ID: 31276836
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Concentrations in plasma clozapine levels in schizophrenic and schizoaffective patients.
    Iglesias García C; Iglesias Alonso A; Bobes J
    Rev Psiquiatr Salud Ment; 2017; 10(4):192-196. PubMed ID: 28844295
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Serum adiponectin concentrations during treatment with olanzapine or risperidone: a pilot study.
    Togo T; Kojima K; Shoji M; Kase A; Uchikado H; Katsuse O; Iseki E; Kosaka K
    Int Clin Psychopharmacol; 2004 Jan; 19(1):37-40. PubMed ID: 15101569
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Screening for diabetes and other metabolic abnormalities in patients with schizophrenia and schizoaffective disorder: evaluation of incidence and screening methods.
    van Winkel R; De Hert M; Van Eyck D; Hanssens L; Wampers M; Scheen A; Peuskens J
    J Clin Psychiatry; 2006 Oct; 67(10):1493-500. PubMed ID: 17107239
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Prevalence of obesity, glucose homeostasis disorders and metabolic syndrome in psychiatric patients taking typical or atypical antipsychotic drugs: a cross-sectional study.
    Mackin P; Watkinson HM; Young AH
    Diabetologia; 2005 Feb; 48(2):215-21. PubMed ID: 15688206
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Metabolic syndrome with the atypical antipsychotics.
    Pramyothin P; Khaodhiar L
    Curr Opin Endocrinol Diabetes Obes; 2010 Oct; 17(5):460-6. PubMed ID: 20717020
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Metabolic adverse effects of olanzapine on cognitive dysfunction: A possible relationship between BDNF and TNF-alpha.
    Zhang C; Fang X; Yao P; Mao Y; Cai J; Zhang Y; Chen M; Fan W; Tang W; Song L
    Psychoneuroendocrinology; 2017 Jul; 81():138-143. PubMed ID: 28477447
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.